RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. (June 2017)

• Record Type: Journal Article
• Authors: Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y.H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Walewski, J.; Fisher, D.; Wang, Y.; Palanca‐Wessels, M.C.; Lin, H.; Liu, Y.; Little, M.; Prince, H.M.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 245
• Page End: 247
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2438_109
• Languages: English
• ISSNs: 0278-0232